Description

Adequan Canine 5ml

Adequan Canine is recommended for the intramuscular treatment of non-infectious degenerative joint disease (DJD) and associated lameness of the carpal and hock joints in horses. Adequan i.m. Equine helps protect and renew joint mobility. It also restores synovial joint lubrication, repairs joint cartilage, reverses the disease cycle, and reduces inflammation.

After administration, Adequan i.m. Equine quickly reaches your horse’s joints to deliver relief and keeps working for up to 96 hours. Adequan i.m. Equine is available in seven 500 mg/5 ml single-use vials and a 100 mg/ml 50 ml multi-dose vial. Adequan i.m. Equine requires a prescription from your veterinarian.

 

Adequan Canine 100mg/ml 5ml

Adequan Canine is an injectable drug approved by the FDA to control symptoms caused by non-infectious traumatic or degenerative arthritis in the synovial joints or after joint surgery.

• Treats equine non-infectious degenerative joint disease (DJD)
• Helps protect and renew joint mobility
• Restores synovial joint lubrication
• Repairs joint cartilage
• Reduces inflammation
• Works quickly after administration

Adequan i.m. Equine rapidly aids in the production of new cartilage which is critical to the performance of the joint. It also facilitates joint movement and decreases local inflammation by restoring synovial lubrication. Adequan i.m. Equine inhibits harmful enzymes that attack synovial fluid and cartilage, reversing the disease processes that cause the loss of cartilage. Adequan I.M. For Horses

 

Which animals/pets is Adequan Canine 100mg/ml 5 ml Vial for?

For use in dogs with joint pain, inflammation, and other canine arthritis-related symptoms. Adequan is ideal for quickly improving joint mobility after surgery. It can also aid in controlling signs of traumatic joint arthritis and degenerative joint diseases.

The safe use of Adequan i.m. Equine in horses used for breeding purposes, during pregnancy, or in lactating mares hasn’t been evaluated. Avoid use in horses with a known hypersensitivity to the contents of Adequan i.m. Equine.Adequan Canine

Adequan i.m. Equine (American Regent Animal Health)

polysulfated glycosaminoglycan (PSGAG)

Adequan Canine 100mg/ml 5 ml Vial uses

Adequan Canine 5ml helps treat non-infectious degenerative joint disease (DJD) and associated lameness of the carpal and hock joints in horses. It is meant to be administered by intramuscular (IM) injection only (syringe is not included). Adequan i.m. Equine requires a prescription from your veterinarian.

Within 2 hours of administration Adequan i.m. Equine reaches peak levels within the joints. Within 48 hours of administration, hyaluronic acid (HA) levels nearly double. Up to 96 hours after administration, Adequan i.m. Equine can be detected in the cartilage and subchondral bone.

Tell your veterinarian if your horse is being used for breeding purposes. If your horse has a known history of hypersensitivity to the contents of Adequan i.m. Equine, let your veterinarian know. If you notice any symptoms of joint discomfort, tell your veterinarian.  Adenosine 50ml Injection

 

Adequan Canine 100mg/ml 5 ml Vial side effects

Studies have shown the following self-limiting and mild reactions in a low number of dogs:

• Transient injection site pain
• Temporary diarrhea
• Abnormal bleeding

These reactions were determined to require no therapy interruption.

Adequan Canine 100mg/ml 5 ml Vial ingredients

Polysulfated Glycosaminoglycan

When administering Adequan i.m. Equine, follow your veterinarian’s instructions exactly as directed. Adequan i.m. Equine must be administered through intramuscular injection only. The recommended dosage schedule is one 500 mg dose every 4 days for 7 treatments.

 

How is Adequan Canine 100mg/ml 5 ml Vial sold?

100 mg/ml 5 ml vial sold in single or double pack.

There are no known contraindications to the use of Adequan i.m. Equine (intramuscular polysulfated glycosaminoglycan). Talk to your veterinarian before giving your horse other medications. King Cobra 100ml

Check out Canine Osteoarthritis